Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology for Johns Hopkins University School of Medicine. Dr. Levy is board certified in medical oncology and hematology by the American Board of Internal Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital. 

2020 CBPD LEVY - Stage IV NSCLC ALK Positive 74 YO Male with Brain Metastasis
dbrock
2020 Case Based Panel Discussion presented by Stephen Liu - 74 year old male with stage lV alk positive NSCLC with brain metastasis, and review of the outcomes of genomic profiling: FISH testing vs NGS
Author
Benjamin Levy, MD, Faculty
Image
For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for specific cases in Lung Cancer.

Dr. Levy is Associate Professor of Oncology and Clinical Director of Medical Oncology and Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, and sits on the board of GRACE. Dr. Liu is Associate Professor of Medicine and Director of Thoracic Oncology and Director of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Dr. Julie Brahmer is Director of the Thoracic Oncology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

For this series, the doctors review cases related to non small cell lung cancer.

In this video, the case discussion is regarding a 74 year old male with stage lV alk positive non small cell lung cancer with brain metastasis. The panel also reviews the outcomes of genomic profiling: FISH testing vs NGS.

 

We thank AstraZeneca Merck Genentech Takeda and Lilly for their support!

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on